RO7239361 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 113 | Muscular dystrophy | 7 |
113. Muscular dystrophy
Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170
Showing 1 to 7 of 7 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-001654-18-DE (EUCTR) | 13/11/2017 | 23/06/2017 | Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361in Ambulatory Boys Wit ... | A randomized, double blind, placebo-controlled, study to assess the efficacy, safety, and tolerability of RO7239361 in ambulatory boys with Duchenne Muscular dystrophy A randomized, double blind, placebo-controlled, study to assess the efficacy, safety, and tolerabili ... | Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchen ... | Product Name: RO7239361 Injections, 7.5 mg/Syringe (10.7 mg/mL) Product Code: RO7239361 INN or Proposed INN: Anti-myostatin Adnectin Other descriptive name: BMS-986089-01, anti-myostatin Product Name: RO7239361 Injections, 15 mg/Syringe (21.4 mg/mL) Product Code: RO7239361 INN or Proposed INN: Anti-myostatin Adnectin Other descriptive name: BMS-986089-01, anti-myostatin Product Name: RO7239361 Injections, 35 mg/Syringe (50 mg/mL) Product Code: RO7239361 INN or Proposed INN: Anti-myostatin Adnectin Other descriptive name: BMS-986089-01, anti-myostatin Product Name: RO7239361 Injections, 50 mg/Syringe (71.4 mg/mL) Product Code: RO7239361 INN or Proposed INN: Anti-myostatin Adnectin Other descriptive name: BMS-986089-01, anti-myostatin Product Name: RO7239361Injections, 7.5 mg/Syringe (10.7 mg/mL) Product Code: RO7239361 INN or Proposed ... | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: no Male: yes | 159 | Phase 3 | United States;Spain;United Kingdom;Italy;France;Canada;Argentina;Belgium;Australia;Germany;Netherlands;Japan;Sweden United States;Spain;United Kingdom;Italy;France;Canada;Argentina;Belgium;Australia;Germany;Netherlan ... | ||
| 2 | EUCTR2016-001654-18-BE (EUCTR) | 10/11/2017 | 26/06/2017 | Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 (BMS-986089) in Ambulatory Boys With Duchenne Muscular Dystrophy Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361(BMS-986089) in Ambula ... | A randomized, double blind, placebo-controlled, study to assess the efficacy, safety, and tolerability of RO7239361 (BMS-986089) in ambulatory boys with Duchenne Muscular dystrophy A randomized, double blind, placebo-controlled, study to assess the efficacy, safety, and tolerabili ... | Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchen ... | Product Name: BMS-986089-01 (RO7239361) Injections, 7.5 mg/Syringe (10.7 mg/mL) Product Code: RO7239361 (BMS-986089) INN or Proposed INN: Anti-myostatin Adnectin Other descriptive name: BMS-986089-01 (RO7239361) , anti-myostatin Product Name: BMS-986089-01 (RO7239361) Injections, 15 mg/Syringe (21.4 mg/mL) Product Code: RO7239361 (BMS-986089) INN or Proposed INN: Anti-myostatin Adnectin Other descriptive name: BMS-986089-01 (RO7239361), anti-myostatin Product Name: BMS-986089-01 (RO7239361) Injections, 35 mg/Syringe (50 mg/mL) Product Code: RO7239361 (BMS-986089) INN or Proposed INN: Anti-myostatin Adnectin Other descriptive name: BMS-986089-01 (RO7239361), anti-myostatin Product Name: BMS-986089-01 (RO7239361) Injections, 50 mg/Syringe (71.4 mg/mL) Product Code: RO7239361 (BMS-986089) INN or Proposed INN: Anti-myostati Product Name: BMS-986089-01 (RO7239361) Injections, 7.5 mg/Syringe (10.7 mg/mL) Product Code: RO72393 ... | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: no Male: yes | 159 | Phase 3 | United States;Spain;Italy;United Kingdom;France;Canada;Argentina;Belgium;Australia;Germany;Netherlands;Japan;Sweden United States;Spain;Italy;United Kingdom;France;Canada;Argentina;Belgium;Australia;Germany;Netherlan ... | ||
| 3 | EUCTR2016-001654-18-GB (EUCTR) | 01/11/2017 | 27/06/2017 | Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361in Ambulatory Boys Wit ... | A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys with Duchenne Muscular Dystrophy A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerabili ... | Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchen ... | Product Name: RO7239361 Injections, 7.5 mg/Syringe (10.7 mg/mL) Product Code: RO7239361 INN or Proposed INN: Anti-Myostatin Adnectin Other descriptive name: BMS-986089-01, Anti-myostatin Product Name: RO7239361 Injections, 15 mg/Syringe (21.4 mg/mL) Product Code: RO7239361 INN or Proposed INN: Anti-Myostatin Adnectin Other descriptive name: BMS-986089-01, anti-myostatin Product Name: RO7239361 Injections, 35 mg/Syringe (50 mg/mL) Product Code: RO7239361 INN or Proposed INN: Anti-Myostatin Adnectin Other descriptive name: BMS-986089-01, anti-myostatin Product Name: RO7239361 Injections, 50 mg/Syringe (71.4 mg/mL) Product Code: RO7239361 INN or Proposed INN: Anti-Myostatin Adnectin Other descriptive name: BMS-986089-01, anti-myostatin Product Name: RO7239361Injections, 7.5 mg/Syringe (10.7 mg/mL) Product Code: RO7239361 INN or Proposed ... | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: no Male: yes | 159 | Phase 3 | United States;Spain;United Kingdom;Italy;France;Canada;Argentina;Belgium;Australia;Germany;Netherlands;Japan;Sweden United States;Spain;United Kingdom;Italy;France;Canada;Argentina;Belgium;Australia;Germany;Netherlan ... | ||
| 4 | EUCTR2016-001654-18-NL (EUCTR) | 26/10/2017 | 12/07/2017 | Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361in Ambulatory Boys Wit ... | A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys with Duchenne Muscular Dystrophy A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerabili ... | Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchen ... | Product Name: RO7239361 Injections, 7.5 mg/Syringe (10.7 mg/mL) Product Code: RO7239361 INN or Proposed INN: Anti-Myostatin Adnectin Other descriptive name: BMS-986089-01, Anti-myostatin Product Name: RO7239361 Injections, 15 mg/Syringe (21.4 mg/mL) Product Code: RO7239361 INN or Proposed INN: Anti-Myostatin Adnectin Other descriptive name: BMS-986089-01, anti-myostatin Product Name: RO7239361 Injections, 35 mg/Syringe (50 mg/mL) Product Code: RO7239361 INN or Proposed INN: Anti-Myostatin Adnectin Other descriptive name: BMS-986089-01, anti-myostatin Product Name: RO7239361 Injections, 50 mg/Syringe (71.4 mg/mL) Product Code: RO7239361 INN or Proposed INN: Anti-Myostatin Adnectin Other descriptive name: BMS-986089-01, anti-myostatin Product Name: RO7239361Injections, 7.5 mg/Syringe (10.7 mg/mL) Product Code: RO7239361 INN or Proposed ... | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: no Male: yes | 159 | Phase 3 | United States;Spain;Italy;United Kingdom;France;Canada;Argentina;Belgium;Australia;Netherlands;Germany;Japan;Sweden United States;Spain;Italy;United Kingdom;France;Canada;Argentina;Belgium;Australia;Netherlands;Germa ... | ||
| 5 | EUCTR2016-001654-18-SE (EUCTR) | 12/08/2017 | 15/06/2017 | Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361in Ambulatory Boys Wit ... | A randomized, double blind, placebo-controlled, study to assess the efficacy, safety, and tolerability of RO7239361 in ambulatory boys with Duchenne Muscular dystrophy A randomized, double blind, placebo-controlled, study to assess the efficacy, safety, and tolerabili ... | Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchen ... | Product Name: RO7239361 Injections, 7.5 mg/Syringe (10.7 mg/mL) Product Code: RO7239361 INN or Proposed INN: Anti-myostatin Adnectin Other descriptive name: BMS-986089-01, Anti-myostatin Product Name: RO7239361 Injections, 15 mg/Syringe (21.4 mg/mL) Product Code: RO7239361 INN or Proposed INN: Anti-myostatin Adnectin Other descriptive name: BMS-986089-01, anti-myostatin Product Name: RO7239361 Injections, 35 mg/Syringe (50 mg/mL) Product Code: RO7239361 INN or Proposed INN: Anti-myostatin Adnectin Other descriptive name: BMS-986089-01, anti-myostatin Product Name: RO7239361 Injections, 50 mg/Syringe (71.4 mg/mL) Product Code: RO7239361 INN or Proposed INN: Anti-myostatin Adnectin Other descriptive name: BMS-986089-01, anti-myostatin Product Name: RO7239361Injections, 7.5 mg/Syringe (10.7 mg/mL) Product Code: RO7239361 INN or Proposed ... | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: no Male: yes | 159 | Phase 3 | United States;Spain;Italy;United Kingdom;France;Canada;Argentina;Belgium;Australia;Germany;Netherlands;Japan;Sweden United States;Spain;Italy;United Kingdom;France;Canada;Argentina;Belgium;Australia;Germany;Netherlan ... | ||
| 6 | NCT03039686 (ClinicalTrials.gov) | July 6, 2017 | 27/1/2017 | Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361in Ambulatory Boys Wit ... | A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerabili ... | Duchenne Muscular Dystrophy | Drug: RO7239361;Drug: Placebo for RO7239361 | Hoffmann-La Roche | NULL | Terminated | 6 Years | 11 Years | Male | 166 | Phase 2/Phase 3 | United States;Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom United States;Argentina;Australia;Belgium;Canada;France;Germany;Italy;Japan;Netherlands;Spain;Sweden ... |
| 7 | NCT02515669 (ClinicalTrials.gov) | December 2, 2015 | 29/7/2015 | Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD | A Multi-Site, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7239361 (BMS-986089) in Ambulatory Boys With Duchenne Muscular Dystrophy A Multi-Site, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Subcutaneous Dose Stu ... | Muscular Dystrophy (DMD) | Drug: RO7239361;Drug: Placebo | Hoffmann-La Roche | NULL | Terminated | 5 Years | 10 Years | Male | 43 | Phase 1/Phase 2 | United States;Canada |